PURPOSE: We analyzed the 23-year Memorial-Sloan Kettering Cancer Center experience with surgical resection, and concurrent adrenalectomy and lymphadenectomy for locally advanced nonmetastatic renal cell carcinoma.
MATERIALS AND METHODS: We retrospectively reviewed the records of 802 patients who underwent nephrectomy with or without concurrent adrenalectomy or lymphadenectomy for locally advanced renal cell carcinoma, defined as stage T3 or greater and M0. Patients who received adjuvant treatment within 3 months of surgery or had fewer than 3 months of followup or bilateral renal masses at presentation were excluded from analysis. Five and 10-year progression-free and overall survival was estimated by the Kaplan-Meier method. Differences between groups were analyzed by the log rank test.
RESULTS: A total of 596 (74%) and 206 patients (26%) underwent radical and partial nephrectomy, respectively. Renal cell carcinoma progressed in 189 patients and 104 died of the disease. Median followup in patients without progression was 4.6 years. Symptoms at presentation, ASA classification, tumor stage, histological subtype, grade and lymph node status were significantly associated with progression-free and overall survival. On multivariate analysis adrenalectomy use decreased with time but lymphadenectomy use increased (OR 0.82 vs 1.16 per year). Larger tumors were associated with a higher likelihood of concurrent adrenalectomy and lymphadenectomy.
CONCLUSIONS: In our series of patients with locally advanced nonmetastatic renal cell carcinoma survival was favorable in those in good health who were asymptomatic at presentation with T3 tumors and negative lymph nodes. Further, there has been a trend toward more selective use of adrenalectomy and increased use of lymphadenectomy.
Written by:
Bazzi WM, Sjoberg DD, Feuerstein MA, Maschino A, Verma S, Bernstein M, O'Brien MF, Jang T, Lowrance W, Motzer RJ, Russo P. Are you the author?
Urology Service, Department of Surgery, Memorial-Sloan Kettering Cancer Center, New York, New York; Department of Epidemiology and Biostatistics, Memorial-Sloan Kettering Cancer Center, New York, New York; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial-Sloan Kettering Cancer Center, New York, New York; Department of Urology, Cork University Hospital, University College Cork, Cork, Ireland; Urology Service, Morristown Surgical Associates, Morristown, New Jersey; Division of Urology, Department of Surgery, University of Utah and Huntsman Cancer Institute, Salt Lake City, Utah.
Reference: J Urol. 2014 Dec 15. pii: S0022-5347(14)05073-3.
doi: 10.1016/j.juro.2014.12.022
PubMed Abstract
PMID: 25524244